Korean Circ J.  2019 Jan;49(1):99-108. 10.4070/kcj.2018.0224.

Assessment of the Clinical Heterogeneity of Kawasaki Disease Using Genetic Variants of BLK and FCGR2A

Affiliations
  • 1Asan Institute for Life Sciences, University of Ulsan College of Medicine, Seoul, Korea. cookie_jklee@hotmail.com
  • 2Department of Pediatrics, Chung-Ang University Hospital, Seoul, Korea.
  • 3Department of Pediatrics, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
  • 4Department of Pediatrics, Kyung Hee University Hospital at Gangdong, Seoul, Korea.
  • 5Department of Pediatrics, Daejeon St. Mary's Hospital, The Catholic University of Korea, Daejeon, Korea.
  • 6Department of Pediatrics, Chungnam National University Hospital, Daejeon, Korea.
  • 7Department of Pediatrics, Seoul National University Children's Hospital, Seoul, Korea.
  • 8Department of Pediatrics, Gangneung Asan Hospital, University of Ulsan College of Medicine, Gangneung, Korea.
  • 9Department of Pediatrics, Inje University Paik Hospital, Busan, Korea.
  • 10Department of Pediatrics, Pusan National University Hospital, Busan, Korea.
  • 11Department of Pediatrics, Korea University Hospital, Seoul, Korea.
  • 12Department of Pediatrics, Ewha Womans University Medical Center, Seoul, Korea.

Abstract

BACKGROUND AND OBJECTIVES
Patients with Kawasaki disease (KD) are clinically heterogeneous because its diagnosis is based solely on clinical observation and there are no definitive biomarkers. We dissected the clinical heterogeneity of KD patients using the KD-associated genetic variants.
METHODS
We performed a genetic association analysis in several KD subgroups categorized by clinical characteristics using the KD-associated variants of the B lymphoid tyrosine kinase (BLK; rs6993775) and Fc gamma receptor II a (FCGR2A; rs1801274) in a large number of case (n=1,011) and control (n=4,533) samples.
RESULTS
BLK and FCGR2A were very significantly associated with KD in Korean KD patients (odds ratio [OR],1.48; p=4.63×10⁻¹¹ for BLK, and OR, 1.26; p=1.42×10⁻⁴ for FCGR2A). However, in KD subgroup analysis, we found that neither BLK nor FCGR2A were associated with either incomplete Kawasaki disease (iKD) type patients or those older than 5 years of age (p>0.2), suggesting that patients with iKD or those older than 5 years of age are a unique subgroup of KD. In genetic association analysis after excluding iKD patients and those older than 5 years old, we found that BLK was associated with all KD subgroups, whereas FCGR2A was specifically associated with male KD patients younger than 1 year of age (OR, 2.22; p=2.35×10⁻⁵).
CONCLUSIONS
KD is a clinically and genetically heterogeneous disease. These findings will provide new insights into the clinical and genetic heterogeneity of KD.

Keyword

Mucocutaneous lymph node syndrome; Genome-wide association study; Polymorphism, single nucleotide

MeSH Terms

Biomarkers
Diagnosis
Genetic Heterogeneity
Genome-Wide Association Study
Humans
Male
Mucocutaneous Lymph Node Syndrome*
Polymorphism, Single Nucleotide
Population Characteristics*
Protein-Tyrosine Kinases
Biomarkers
Protein-Tyrosine Kinases

Reference

1. Kawasaki T, Kosaki F, Okawa S, Shigematsu I, Yanagawa H. A new infantile acute febrile mucocutaneous lymph node syndrome (MLNS) prevailing in Japan. Pediatrics. 1974; 54:271–276.
2. Burns JC, Kushner HI, Bastian JF, et al. Kawasaki disease: a brief history. Pediatrics. 2000; 106:E27.
Article
3. Makino N, Nakamura Y, Yashiro M, et al. Descriptive epidemiology of Kawasaki disease in Japan, 2011–2012: from the results of the 22nd nationwide survey. J Epidemiol. 2015; 25:239–245.
4. Huang WC, Huang LM, Chang IS, et al. Epidemiologic features of Kawasaki disease in Taiwan, 2003–2006. Pediatrics. 2009; 123:e401–5.
Article
5. Kim GB, Han JW, Park YW, et al. Epidemiologic features of Kawasaki disease in South Korea: data from nationwide survey, 2009–2011. Pediatr Infect Dis J. 2014; 33:24–27.
6. Burns JC, Glodé MP. Kawasaki syndrome. Lancet. 2004; 364:533–544.
Article
7. McCrindle BW, Rowley AH, Newburger JW, et al. Diagnosis, treatment, and long-term management of Kawasaki disease: a scientific statement for health professionals from the American Heart Association. Circulation. 2017; 135:e927–e999.
Article
8. Burns JC, Capparelli EV, Brown JA, Newburger JW, Glode MP. Intravenous gamma-globulin treatment and retreatment in Kawasaki disease. Pediatr Infect Dis J. 1998; 17:1144–1148.
Article
9. Kato H, Sugimura T, Akagi T, et al. Long-term consequences of Kawasaki disease. A 10- to 21-year follow-up study of 594 patients. Circulation. 1996; 94:1379–1385.
10. Newburger JW, Takahashi M, Burns JC, et al. The treatment of Kawasaki syndrome with intravenous gamma globulin. N Engl J Med. 1986; 315:341–347.
Article
11. Durongpisitkul K, Gururaj VJ, Park JM, Martin CF. The prevention of coronary artery aneurysm in Kawasaki disease: a meta-analysis on the efficacy of aspirin and immunoglobulin treatment. Pediatrics. 1995; 96:1057–1061.
12. Yanagawa H, Nakamura Y, Yashiro M, et al. A nationwide incidence survey of Kawasaki disease in 1985–1986 in Japan. J Infect Dis. 1988; 158:1296–1301.
Article
13. Fujita Y, Nakamura Y, Sakata K, et al. Kawasaki disease in families. Pediatrics. 1989; 84:666–669.
14. Uehara R, Yashiro M, Nakamura Y, Yanagawa H. Clinical features of patients with Kawasaki disease whose parents had the same disease. Arch Pediatr Adolesc Med. 2004; 158:1166–1169.
Article
15. Khor CC, Davila S, Breunis WB, et al. Genome-wide association study identifies FCGR2A as a susceptibility locus for Kawasaki disease. Nat Genet. 2011; 43:1241–1246.
16. Tsai FJ, Lee YC, Chang JS, et al. Identification of novel susceptibility Loci for Kawasaki disease in a Han Chinese population by a genome-wide association study. PLoS One. 2011; 6:e16853.
Article
17. Lee YC, Kuo HC, Chang JS, et al. Two new susceptibility loci for Kawasaki disease identified through genome-wide association analysis. Nat Genet. 2012; 44:522–525.
Article
18. Onouchi Y, Ozaki K, Burns JC, et al. A genome-wide association study identifies three new risk loci for Kawasaki disease. Nat Genet. 2012; 44:517–521.
19. Chang CJ, Kuo HC, Chang JS, et al. Replication and meta-analysis of GWAS identified susceptibility loci in Kawasaki disease confirm the importance of B lymphoid tyrosine kinase (BLK) in disease susceptibility. PLoS One. 2013; 8:e72037.
20. Kim JJ, Yun SW, Yu JJ, et al. A genome-wide association analysis identifies NMNAT2 and HCP5 as susceptibility loci for Kawasaki disease. J Hum Genet. 2017; 62:1023–1029.
21. Dajani AS, Taubert KA, Takahashi M, et al. Guidelines for long-term management of patients with Kawasaki disease. Report from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association. Circulation. 1994; 89:916–922.
Article
22. Purcell S, Cherny SS, Sham PC. Genetic Power Calculator: design of linkage and association genetic mapping studies of complex traits. Bioinformatics. 2003; 19:149–150.
Article
23. Sonobe T, Kiyosawa N, Tsuchiya K, et al. Prevalence of coronary artery abnormality in incomplete Kawasaki disease. Pediatr Int. 2007; 49:421–426.
Article
24. Yellen ES, Gauvreau K, Takahashi M, et al. Performance of 2004 American Heart Association recommendations for treatment of Kawasaki disease. Pediatrics. 2010; 125:e234–e241.
Article
25. Kim GB, Park S, Eun LY, et al. Epidemiology and clinical features of Kawasaki disease in South Korea, 2012–2014. Pediatr Infect Dis J. 2017; 36:482–485.
Article
26. Vigato-Ferreira IC, Toller-Kawahisa JE, Pancoto JA, et al. FcγRIIa and FcγRIIIb polymorphisms and associations with clinical manifestations in systemic lupus erythematosus patients. Autoimmunity. 2014; 47:451–458.
Article
27. Warmerdam PA, van de Winkel JG, Vlug A, Westerdaal NA, Capel PJ. A single amino acid in the second Ig-like domain of the human Fc gamma receptor II is critical for human IgG2 binding. J Immunol. 1991; 147:1338–1343.
28. Parren PW, Warmerdam PA, Boeije LC, et al. On the interaction of IgG subclasses with the low affinity Fc gamma RIIa (CD32) on human monocytes, neutrophils, and platelets. Analysis of a functional polymorphism to human IgG2. J Clin Invest. 1992; 90:1537–1546.
Article
29. Kwon KS, Cho HY, Chung YJ. Recapitulation of candidate systemic lupus erythematosus-associated variants in Koreans. Genomics Inform. 2016; 14:85–89.
Article
Full Text Links
  • KCJ
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr